SecBot SecBot
8-K ·Filed Sep 11, 2026

TCRX

TScan Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed2mo ago SEC0001193125-26-388631
Actionable Insight • Neutral

The retention program is a necessary step to prevent further leadership exodus after the 75% workforce reduction and CFO/CMO termination. The heavy reliance on a 'Financing Milestone' for RSU vesting signals that the company urgently needs to raise capital. Monitor for a dilutive equity offering or partnership deal, as the cash runway extension to Q4 2027 depends on it.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$0.3204
T+0 close · Sep 11, 2026 · via day close
Latest settled
−25.72%
T+20 · $0.2380 · next T+60 in 20d
Vs SPY
−27.59%
α at T+20
Latest observation
−49.16%
T+46 · FF3 residual α
  1. T+0 · Sep 11 $0.3204entry
  2. T+1 · 2mo ago −4.40%α −3.95% · $0.3063
  3. T+5 · 2mo ago −2.65%α −2.43% · $0.3119
  4. T+20 · 6w ago −25.72%α −27.59% · $0.2380
  5. T+46 · todayOpen
  6. T+60 · in 20d Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

TScan Therapeutics filed an 8-K on September 11, 2026, disclosing a retention program approved by the Compensation Committee on September 8, 2026. The program provides CEO Gavin MacBeath with a cash award of $822,000 and 2,400,000 RSUs, and Chief Legal & Strategy Officer Zoran Zdraveski with a cash award of $416,000 and 1,050,000 RSUs. Vesting of the RSUs is tied to a future financing milestone, and half of the cash awards are contingent on clinical milestones for the in vivo solid tumor program. This filing follows a severe restructuring 9 days prior that included a 75% workforce reduction, termination of the CFO and CMO, and a Nasdaq delisting notice, making this retention program a critical attempt to stabilize leadership during acute financial distress.

Key Facts

  • CEO Gavin MacBeath receives a cash award of $822,000 and 2,400,000 RSUs under the retention program.
  • Chief Legal & Strategy Officer Zoran Zdraveski receives a cash award of $416,000 and 1,050,000 RSUs.
  • RSU vesting is contingent on achieving a 'Financing Milestone'; half of cash awards depend on a 'Clinical Milestone' for the in vivo solid tumor program.
  • This retention program was approved on September 8, 2026, just 9 days after a restructuring that cut 75% of the workforce and terminated the CFO and CMO.
  • The program is designed to retain key employees needed to support the company following the restructuring.

Financial Impact

Cash awards of $1.238M total ($822K CEO + $416K CLO) plus 3.45M RSUs (2.4M CEO + 1.05M CLO) with vesting tied to financing and clinical milestones.

cash compensationshare-based compensationdilution

Risk Factors

  • Failure to achieve the Financing Milestone would leave RSUs unvested, potentially triggering further executive departures.
  • The $1.238M in cash awards consumes limited cash reserves, shortening the runway if the clinical milestone is not met.
  • Massive potential dilution from 3.45M RSUs (significant relative to the $20M market cap) if the Financing Milestone is achieved.
  • Nasdaq delisting risk remains unresolved and could accelerate if financing fails.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
77% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (TCRX), Batch item 10001193125-26-388631
Document: 0001193125-26-388631-index-headers.html0001193125-26-388631
Document: 0001193125-26-388631-index.html0001193125-26-388631
Document: 0001193125-26-388631.txt0001193125-26-388631
8-K Filing (TCRX), Batch item 50001193125-26-388631
Document: 0001193125-26-388631-index-headers.html0001193125-26-388631
Document: 0001193125-26-388631-index.html0001193125-26-388631
Document: 0001193125-26-388631.txt0001193125-26-388631

Track record

15 reports on TCRX

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +77.60% at T+60 after the Aug 18, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 7/10 Entry $0.1680 Now $0.1450 +13.69% settles Nov 19
  2. Oct 26, 202621d ago DEF 14A Bearish 6/10 Entry $0.1897 to $0.1745 Now $0.1450 +23.56% ▲ +8.01% +6.75% vs SPY
  3. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $0.2102 to $0.1897 Now $0.1450 −31.02% ▼ −9.75% −9.61% vs SPY
  4. Sep 30, 20266w ago 8-K Neutral 2/10 Entry $0.3175 to $0.2282 Now $0.1450 −54.33% ▼ −28.13% −29.43% vs SPY
  5. Sep 25, 20267w ago SC 13G Neutral 3/10 Entry $0.3400 to $0.2953 Now $0.1450 −57.35% ▼ −13.15% −14.35% vs SPY
  6. Sep 11, 20269w ago 8-K Neutral 5/10 Viewing Entry $0.3204 to $0.3119 Now $0.1450 −54.74% ▼ −2.65% −2.43% vs SPY
  7. Sep 2, 202610w ago 8-K Bearish 7/10 Entry $0.3810 to $0.3179 Now $0.1450 +61.94% ▲ +16.56% +15.60% vs SPY
  8. Aug 18, 202612w ago 8-K Bearish 7/10 Entry $0.7500 to $0.7774 Now $0.1450 +80.67% ▼ −3.65% −4.04% vs SPY
  9. Aug 12, 202613w ago 8-K Bearish 6/10 No price data
  10. Aug 12, 202613w ago Press Release Bearish 6/10 Entry $0.7730 to $0.7500 Now $0.1450 +81.24% ▲ +2.98% +2.53% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 11, 2026